Deciphera Pharmaceuticals Develops QINLOCK ripretinib for the Treatment of FourthLine Gastrointestinal Stromal Tumors in Adults

Deciphera Pharmaceuticals developed QINLOCK™ (ripretinib) 50mg capsules to treat adult patients with advanced gastrointestinal stromal tumour (GIST) who underwent prior treatment with three or more kinase inhibitors, including imatinib.

A gastrointestinal stromal tumour is a type of tumour existing in gastrointestinal tract, stomach or small intestine, formed due to the development of specialised cells in the gastrointestinal tract called interstitial cells.Its symptoms include weight loss, low red blood cell counts (anaemia), weakness, tiredness, pain or swelling in the abdomen, vomiting, nausea, black and tarry stools and vomiting of blood.

QINLOCK is a tyrosine kinase inhibitor, which majorly stops the growth of KIT kinase and PDGFRα kinase including primary and secondary mutations. The drug targets a broad spectrum of KIT and PDGFRα mutations that activate GIST.QINLOCK is handy in the form of oral tablets, a prescribeddose of 150mg taken once daily with or without food.

Some of the adverse reactions of QINLOCK include vomiting, nausea, alopecia (hair loss), abdominal pain, fatigue, decreased appetite, myalgia (muscle pain), constipation, diarrhoea and palmar-plantar erythrodysesthesia syndrome (a skin reaction in the palms and soles).

QINLOCK is clinically proven and essentially a new promising therapy for patients with high unmet demand who have previously undergone traditional tyrosine kinase inhibitors for complicated GIST disease.